This interview discusses Little Green Pharma’s (ASX:LGP) record-breaking quarterly results for June 2024, highlighting a 12% increase in revenue and significant cash receipts. CEO Paul Long elaborates on the company’s growth drivers, including new product sales in Australia and Europe, and outlines their strategy to maintain market share and expand in emerging European markets.
More From The Market Online
ASX Market Close: IT stocks lead index higher | January 22, 2025
This was a seven-week closing high, achieved amidst positive sentiment as investors react to Donald Trump’s…
- Sean Boss
- 2 mins
- 22 January 2025 16:51 (AEDT)
Wednesday notes: NEXTDC jumps on Trump’s $500B AI spend plan; JB Hi-Fi hits new record
It was a day not without its big-name earnings from the likes of Bubs (ASX:BUB) and
- Jonathon Davidson
- 2 mins
- 22 January 2025 17:12 (AEDT)
200k new housing starts in 2026: UBS sees upside for construction, but are home prices too high?
In a new Global Research note from a team of UBS analysts headed by Economist George Tharenou, UBS sees “upside risk” for the
- Jonathon Davidson
- 2 mins
- 22 January 2025 16:53 (AEDT)
Etherstack signs US$1.2M deal with telecom giant AT&T, shares jump 12%
Etherstack Plc has signed a US$1.2M contract with global telecommunications carrier giant AT&T, pushing its shares…
- Caroline Smith
- 1 min
- 22 January 2025 15:10 (AEDT)